Jacob Haling
Jacob Haling has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Adam J. Elliott
Mirati Therapeutics, Inc., San Diego, California. 1
29 shared publications - Allan Hebbert
Mirati Therapeutics, Inc 92121 San Diego CA USA
29 shared publications - Andrew Calinisan
Mirati Therapeutics (United States), San Diego, CA, United States
29 shared publications - Anthony Ivetac
Mirati Therapeutics, Inc 92121 San Diego CA USA
29 shared publications - Barbara Saechao
Mirati Therapeutics, Inc 92121 San Diego CA USA
29 shared publications - Christopher R. Smith
Mirati Therapeutics, Inc 92121 San Diego CA USA
29 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (46) , 4990-5001
Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses
KRAS is mutated in 30% of all human cancers. Small molecule inhibitors targeting KRAS with distinct mechanisms-of-action and variable specificities have entered the clinic, but their full effect on the RAS signaling network remains unclear. Here, we described the impact of RAS inhibition on the KRAS interactome using Proximity-dependent Biotin Identification. Two inhibitors were used: panRAS-ON, which forms a ternary complex between cyclophilin and RAS in the GTP-bound state; panKRAS-off, which binds to the KRAS switch II pocket. RAS inhibitors were found to significantly alter 16.5% of proteins in proximity to KRAS. Despite their distinct modality, the KRAS inhibitors induced highly correlated changes in the KRAS interactomes. Among KRAS-proximal proteins, Afadin was highly affected by RAS inhibition. AFDN is a key regulator of cell motility, invasion, and metastasis. Analysis of AFDN phosphorylation revealed that AKT only partially modulates p-Ser1718, while KRAS inhibition sufficiently abolished EGF-mediated AFDN phosphorylation. Silencing AFDN in a KRAS-driven non-small cell lung cancer model abolished chemotaxis and disrupted directional migration in an EGF-driven wound healing model. We demonstrated that KRAS is a central node in regulating growth factor-induced cell migration, and that KRAS inhibition plays a broader role than MAPK-mediated cell proliferation and survival.
- 16 October 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (46) , 4990-5001
Open AccessDynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses
KRAS is mutated in 30% of all human cancers. Small molecule inhibitors targeting KRAS with distinct mechanisms-of-action and variable specificities have entered the clinic, but their full effect on the RAS signaling network remains unclear. Here, we described the impact of RAS inhibition on the KRAS interactome using Proximity-dependent Biotin Identification. Two inhibitors were used: panRAS-ON, which forms a ternary complex between cyclophilin and RAS in the GTP-bound state; panKRAS-off, which binds to the KRAS switch II pocket. RAS inhibitors were found to significantly alter 16.5% of proteins in proximity to KRAS. Despite their distinct modality, the KRAS inhibitors induced highly correlated changes in the KRAS interactomes. Among KRAS-proximal proteins, Afadin was highly affected by RAS inhibition. AFDN is a key regulator of cell motility, invasion, and metastasis. Analysis of AFDN phosphorylation revealed that AKT only partially modulates p-Ser1718, while KRAS inhibition sufficiently abolished EGF-mediated AFDN phosphorylation. Silencing AFDN in a KRAS-driven non-small cell lung cancer model abolished chemotaxis and disrupted directional migration in an EGF-driven wound healing model. We demonstrated that KRAS is a central node in regulating growth factor-induced cell migration, and that KRAS inhibition plays a broader role than MAPK-mediated cell proliferation and survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S2 shows the antitumor activity of MRTX0902 in the LN229 (PTPN11 A72S-mutant) model, with tumor growth inhibition data displayed in Figure S2A and ERK phosphorylation graphed in Figure S2B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S2 shows the antitumor activity of MRTX0902 in the LN229 (PTPN11 A72S-mutant) model, with tumor growth inhibition data displayed in Figure S2A and ERK phosphorylation graphed in Figure S2B.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S1 details the genetic vulnerabilities and modifiers of response associated with combination treatment of MRTX0902 with adagrasib in the KRAS G12C-mutant MIA PaCa-2 (S1A, S1B, S1D, and S1E) and LU99 (S1C) cell lines in vitro and in vivo.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S1 details the genetic vulnerabilities and modifiers of response associated with combination treatment of MRTX0902 with adagrasib in the KRAS G12C-mutant MIA PaCa-2 (S1A, S1B, S1D, and S1E) and LU99 (S1C) cell lines in vitro and in vivo.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S8 details the antitumor effects associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S8 details the antitumor effects associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S1 details the efficacy of MRTX0902 in a panel of cancer cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S1 details the efficacy of MRTX0902 in a panel of cancer cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Materials and Methods section includes detailed protocols for the following: Experimental Preparation of MRTX0902 and Avutometinib, SOS1 Biochemical Binding Assay, SOS1 and SOS2 Functional Assays, KRAS-SOS1 Protein-Protiein Interaction (PPI) HTRF Assay, In-Cell Western Assay, 3D Ultra-Low Attachment (ULA) Viability Assay, Immunoblotting and Densitometry Analysis, DUSP6 Quantification from Naive and Tumor-Bearing Mouse Blood, Bioanalysis and Pharmacokinetic Analysis, Synergy Analysis, CRISPR/Cas9 Screening and Data Analysis Methodology, RNAseq Pre-Processing, RNAseq Data Analysis, and Whole Genome Sequencing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Materials and Methods section includes detailed protocols for the following: Experimental Preparation of MRTX0902 and Avutometinib, SOS1 Biochemical Binding Assay, SOS1 and SOS2 Functional Assays, KRAS-SOS1 Protein-Protiein Interaction (PPI) HTRF Assay, In-Cell Western Assay, 3D Ultra-Low Attachment (ULA) Viability Assay, Immunoblotting and Densitometry Analysis, DUSP6 Quantification from Naive and Tumor-Bearing Mouse Blood, Bioanalysis and Pharmacokinetic Analysis, Synergy Analysis, CRISPR/Cas9 Screening and Data Analysis Methodology, RNAseq Pre-Processing, RNAseq Data Analysis, and Whole Genome Sequencing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S5 details the antitumor activity of MRTX0902 and avutometinib in human KRAS-MAPK pathway mutant tumor cell line-derived xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S5 details the antitumor activity of MRTX0902 and avutometinib in human KRAS-MAPK pathway mutant tumor cell line-derived xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S4 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S4 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S4 shows the antitumor activity of MRTX0902 and osimertinib in human EGFR-mutant tumor cell line-derived xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S4 shows the antitumor activity of MRTX0902 and osimertinib in human EGFR-mutant tumor cell line-derived xenograft models.